ViMRT
}  
 
Home   
< Docs   

 HIV mutation literature information.


  Unique thermodynamic response of tipranavir to human immunodeficiency virus type 1 protease drug resistance mutations.
 PMID: 17360759       2007       Journal of virology
Abstract: Characterization of tipranavir binding to wild-type protease, active site mutants I50V and V82F/I84V, the multidrug-resistant mutant L10I/L33I/M46I/I54V/L63I/V82A/I84V/L90M, and the tipranavir in vitro-selected mutant I13V/V32L/L33F/K45I/V82L/I84V was performed by isothermal titration calorimetry and crystallography.


  Food and Drug Administration analysis of tipranavir clinical resistance in HIV-1-infected treatment-experienced patients.
 PMID: 17197808       2007       AIDS (London, England)
Abstract: The most common protease mutations that developed in tipranavir-treated individuals who experienced virologic failure were L10I/V/S, I13V, L33V/I/F, M36V/I/L V82T, V82L, and I84V.


  Tipranavir: a ritonavir-boosted protease inhibitor.
 PMID: 16060700       2005       Drugs
Abstract: Analysis of clinical isolates from treatment-experienced patients identified the following tipranavir resistance-associated HIV protease mutations: L10V, I13V, K20M/R/V, L33F, E35G, M36I, K43T, M46L, I47V, I54A/M/V, Q58E, H69K, T74P, V82L/T, N83D, I84V.


  Selection and characterization of HIV-1 showing reduced susceptibility to the non-peptidic protease inhibitor tipranavir.
 PMID: 16122817       2005       Antiviral research
Abstract: At the end of the selection experiments, viruses harbouring 10 mutations in the protease (L10F, I13V, V32I, L33F, M36I, K45I, I54V, A71V, V82L, I84V) as well as a mutation in the CA/SP1 gag cleavage site were selected and showed 87-fold decreased susceptibility to tipranavir.



Browser Board

 Co-occurred Entities




   Filtrator